The Chain: Protein Engineering Podcast

EXPLORE

Society & Culture

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/4d/16/c6/4d16c616-143e-c84a-fade-0e6271d76b78/mza_5520285442793437152.jpg/600x600bb.jpg

The Chain: Protein Engineering Podcast

Cambridge Healthtech Institute

80 episodes

2 weeks ago

September 16, 2025 | With the rise of AI and automation, what is the core human skill in drug discovery that is and will be valuable in the future? Derek Lowe, director of Chemical Biology Therapeutics at Novartis and author of the In the Pipeline blog, discusses the impact of AI—and non-AI technologies—on the business of drug making. With host Christopher Bahl, cofounder and CEO of AI Proteins, their conversation covers the value of a PhD in the tech world today, the long-term impacts of kno...

Show more...

All content for The Chain: Protein Engineering Podcast is the property of Cambridge Healthtech Institute and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

September 16, 2025 | With the rise of AI and automation, what is the core human skill in drug discovery that is and will be valuable in the future? Derek Lowe, director of Chemical Biology Therapeutics at Novartis and author of the In the Pipeline blog, discusses the impact of AI—and non-AI technologies—on the business of drug making. With host Christopher Bahl, cofounder and CEO of AI Proteins, their conversation covers the value of a PhD in the tech world today, the long-term impacts of kno...

Show more...

Episodes (20/80)

The Chain: Protein Engineering Podcast

Episode: 77 - Derek Lowe on AI and the US Biotech Ecosystem

September 16, 2025 | With the rise of AI and automation, what is the core human skill in drug discovery that is and will be valuable in the future? Derek Lowe, director of Chemical Biology Therapeutics at Novartis and author of the In the Pipeline blog, discusses the impact of AI—and non-AI technologies—on the business of drug making. With host Christopher Bahl, cofounder and CEO of AI Proteins, their conversation covers the value of a PhD in the tech world today, the long-term impacts of kno...

23 hours ago

42 minutes

The Chain: Protein Engineering Podcast

Alexey Lugovskoy Shares Decades of Experience in Starting Out and Founding Companies

August 12, 2025 | Diagonal Therapeutics founder and CEO Alexey Lugovskoy discusses the key lessons learned over his illustrious career, starting from his childhood in the Soviet Union to founding his own company, Diagonal Therapeutics. With host Tariq Ghayur, Lugovskoy shares insights gained from working with organizations of different sizes, taking on the obstacles of building a pipeline, and integrating AI/ML into discovery programs, as well as his most memorable achievement—and most memora...

1 month ago

47 minutes

The Chain: Protein Engineering Podcast

Episode: 75 - Are Licensing Fees Required or Gatekeeping?

July 15, 2025 | Are licensing fees required or gatekeeping? In this episode of The Chain, host Nimish Gera, vice president of Biologics at Mythic Therapeutics, and Ian Wilkinson, CEO of Gamma Proteins, discuss accessing antibody discovery technology through licensing fees and royalties—and whether these fees are justified or not. Wilkinson delves into the current landscape of antibody discovery technologies, including if AI-based technology warrants fees, how royalties affect both small compa...

1 month ago

32 minutes

The Chain: Protein Engineering Podcast

Episode: 74 - Keith Flaherty, President-Elect of AACR, on Public and Private Collabs, AI Optimism, and More

June 10, 2025 | In this bonus episode of The Chain, Daniel Chen, MD, PhD, founder and CEO of Synthetic Design Lab, returns for the Science Commune segment and speaks with Keith Flaherty, MD, FAACR, professor of Medicine of Harvard Medical School and president-elect of AACR. They discuss Flaherty’s prolific career; how his background led him to pursue a career in medicine; how public and private sectors are coming together in oncology around collaborations; reflections on targeted therapies an...

3 months ago

47 minutes

The Chain: Protein Engineering Podcast

Episode: 73 - PANEL DISCUSSION: Near-Term Challenges for AI/ML in Biotherapeutic R&D

June 10, 2025 | This episode of The Chain features a panel discussion from May’s PEGS Boston. Moderated by Peter Tessier, Albert M. Mattocks professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, the panelists include Sarel Fleishman, professor of Biomolecular Sciences at the Weizmann Institute of Science; Kadina Johnston, senior specialist of Discovery Biologics at Merck & Co.; Vincent Ling, chief business officer of Morphocell Technologies; Arvind R...

3 months ago

1 hour 1 minute

The Chain: Protein Engineering Podcast

Episode: 72 - Pamela Barney on HR Lessons to Meet the Needs of Biotech

In this episode of The Chain, host Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC, talks with Pamela Barney, former associate director of HR, AbbVie, about her career within biotech/pharma organizations and some key lessons learned, such as taking advantage of your contacts and network, managing diverse workforces, and HR’s role in creating an engaged team. Barney also discusses why she entered the HR field and the challenges of culture changes when transitioning from a small organization to...

4 months ago

35 minutes

The Chain: Protein Engineering Podcast

PEGS Young Scientist Keynote Jessica Stark on the Role of Glycans in Cancer Research

In this episode of The Chain, host Brandon DeKosky, associate professor, speaks with MIT colleague Jessica Stark, Underwood-Prescott career development professor, about glycans and why they are important in cancer research. Stark discusses how she became interested in immunology, what her PhD and post-doctoral training was like, her thoughts on singlets operating as part of a network of checkpoint molecules, and what’s currently going on in glycobiology. She also talks about her keynote prese...

5 months ago

28 minutes

The Chain: Protein Engineering Podcast

Episode: 70 - Views on Machine Learning and AI in the Antibody and Protein Engineering Space

March 11, 2025 | In this episode of The Chain, host Andrew Buchanan, principal scientist at AstraZeneca, and Andreas Plückthun, professor and head of biochemistry at the University of Zurich, discuss AI/ML technologies in the antibody and protein engineering space. Plückthun shares his perspectives on what technologies show promise and success, why the definition of epitope is important when developing a drug, and what aspects he expects to improve in the ML field in the future.

6 months ago

49 minutes

The Chain: Protein Engineering Podcast

Episode: 69 - Conversation with Sir Greg Winter on the 50th Anniversary of the Milstein and Köhler Paper

February 21, 2025 | This episode marks the 50th anniversary of one of the most influential papers in biomedical science—the 1975 Milstein and Köhler paper on hybridoma technology, which paved the way for monoclonal antibodies. Ralph Minter, Biotech CSO/CTO, discusses this important milestone with a true pioneer in the field, Sir Greg Winter, Nobel Laureate and one of the key figures in the development of therapeutic antibodies.

6 months ago

50 minutes

The Chain: Protein Engineering Podcast

Episode: 68 - Changing the Game of Protein-Protein Interactions With Randolph Lopez

In this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company’s platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez a...

9 months ago

46 minutes

The Chain: Protein Engineering Podcast

Episode: 67 - Anthony Tolcher Discusses Oncology, Dual-Payload Technology, and the ADC Field

November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload technologies, the potency of new payloads, and bispecific targeting. Tolcher also shares what inspired him to pursue oncology, how he came across ADCs,...

10 months ago

42 minutes

The Chain: Protein Engineering Podcast

Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond

October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the ...

11 months ago

39 minutes

The Chain: Protein Engineering Podcast

Episode 65- Tariq Ghayur on the Renaissance of Bispecifics and ADCs, AI, and More

September 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, founder of FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his journey from BASF Pharma to AbbVie, what it was like when the industry shifted its focus from small molecules to biologics, and the major differenc...

1 year ago

31 minutes

The Chain: Protein Engineering Podcast

Episode: 64 - Peyton Greenside on AI’s Role in Antibody Engineering, Optimization, and More

In this episode of The Chain, host Nimish Gera, Ph.D., vice president of biologics at Mythic Therapeutics, speaks with Peyton Greenside, CSO and co-founder of BigHat Biosciences, about the role of AI and machine learning in antibody engineering and targeting complex modalities, including bispecifics and ADCs. Greenside also discusses the work her organization does, what BigHat is doing to ensure the quality of data to train their AI models with, the methods of approaching harder targets such ...

1 year ago

32 minutes

The Chain: Protein Engineering Podcast

Episode: 63 - Discussing Protein Signaling and Structural Biology With Andrew Kruse

In this episode of The Chain, host Brandon DeKosky, associate professor at MIT, speaks with Andrew Kruse, PhD, professor of biological chemistry and molecular pharmacology at Harvard University, about protein signaling and structural biology. Kruse explains what exactly bias signaling is and discusses the problems he and his team are working to resolve, as well as the tools they use to work out the dynamics of structures. He also shares the findings in signaling receptors and biology that he’...

1 year ago

38 minutes

The Chain: Protein Engineering Podcast

Episode: 62 - AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype

his special episode of The Chain features a panel of industry experts who discussed AI and ML in antibody discovery and engineering at this year’s PEGS Boston event. Peter Tessier, professor at the University of Michigan; Andrew Bradbury, CSO at Specifica; Andrew Waight, Senior Director of Machine Learning, Discovery Biologics & Protein Sciences at Merck Research Labs; Peyton Greenside, Co-Founder & CSO of BigHat Biosciences; and Paolo Marcatili, Director of Antibody Design at Novo No...

1 year ago

1 hour 3 minutes

The Chain: Protein Engineering Podcast

Episode: 61 - Tomoyuki Igawa Discusses Leadership and His Experiences in Discovery and Development

In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, speaks with Tomoyuki Igawa, PhD, chief executive officer, Chugai Pharmabody Research in Singapore, about his 20+ years of experience in drug discovery and development. Igawa possesses a unique perspective that has allowed him and his team to develop innovative concepts, such as recycling sweeping antibodies and bispecific platforms. He discusses how the discovery and developm...

1 year ago

55 minutes

The Chain: Protein Engineering Podcast

Episode: 60 - Lesley Millar-Nicholson on Technology Licensing, Navigating Patents, and Building Teams

This month The Chain shares a recent episode of the Lab Rats to Unicorns podcast. Lab Rats to Unicorns, hosted by John Flavin, aims to demystify the process of creating a great company in the life sciences, biotech, medtech, clean energy, and beyond. In this episode, Flavin speaks with Lesley Millar-Nicholson, executive director of MIT’s Technology Licensing Office (TLO). Millar-Nicholson discusses the role of the TLO, what happens after a patent is filed and licensed to a company or start-up...

1 year ago

48 minutes

The Chain: Protein Engineering Podcast

Episode: 59 - Gabriel Rocklin on Protein Biophysics and Protein Design

In this month’s episode of The Chain, host Ben Hackel, professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Gabriel Rocklin, assistant professor of Pharmacology at Northwestern University, about two recently published papers from Rocklin’s lab: one on advancing the ability to design challenging typologies and one on developing and leveraging a new technique on high-throughput protein biophysics. Rocklin shares the journey from ideation to reali...

1 year ago

33 minutes

The Chain: Protein Engineering Podcast

Episode: 58 - Janine Schuurman Reflects on the Key Lessons and Accomplishments of Her 20-Year Career

How does one maintain innovation in the antibody industry? In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, talks with Janine Schuurman, PhD, president of The Antibody Society, independent biotech consultant and founder of Lust for Life Sciences, about her inspiration to get into antibody engineering, her impressive career at Genmab, advice for a productive work environment, and her current work. Dr. Schuurman also shares i...

1 year ago

55 minutes